Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis.

Abstract

The primary objective of the present study was to correlate blood cell counts (lymphocyte, monocyte and platelet counts) with early disease relapse following the attainment of complete remission (CR) by the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP)-like regimen in patients with advanced diffuse large B-cell lymphoma (DLBCL). In total, 30 patients were evaluated, with a median follow-up period of 43 months. All the participating patients attained CR. In total, eight patients experienced relapse within two years of the diagnosis, and the three-year overall survival rate was recorded as 77%. The peripheral counts for lymphocytes, monocytes and platelets, and the lymphocyte-monocyte ratio, all of which have been reported to be prognostic in DLBCL, were assessed. None of these parameters were correlated with the incidence of early relapse or with the prognosis. The lymphocyte count was higher in the patients with durable remission than in those who relapsed, however, no significant differences were identified. Thus, the present study concluded that early disease relapse was not predicted by peripheral blood cell counts in advanced DLBCL that reached CR using the R-CHOP-like regimen.

• Authors: Takahiro Yamauchi, Toshiki Tasaki, Katsunori Tai, Satoshi Ikegaya, Kazutaka Takagi, Eiju Negoro, Shinji Kishi, Akira Yoshida, Hiromichi Iwasaki, Takanori Ueda
• Journal: Oncology letters (Oncol Lett) Vol. 9 Issue 2 Pg. 851-856 (Feb 2015) ISSN: 1792-1074 [Print] Greece
• PMID: 25621059 (Publication Type: Journal Article)